L’ormone Erythropoietin è conosciuto meglio come il dopante EPO. Scienziati dell’università di Heidelberg hanno scoperto, che l’EPO protegge le cellule durante una neurite ottica. Un infiammazione del nervo ottico spesso è uno dei primi sintomi della SM. Durante le sue ricerche il primario della clinica neurologica universitaria di Heidelberg ha scoperto che l’EPO incentiva la sopravvivenza delle cellule della retina e del nervo ottico durante l’infiammazione. Nel 2012 è stato fatto uno studio su 40 pazienti affetti da SM. Oltre alla terapia “standard” di cortisone gli è stato somministrato l’EPO per la durata di tre giorni. Su questi pazienti morirono decisamente meno cellule che nel gruppo curato solo con il cortisone. Questo nuovo approccio terapeutico sarà riesaminato presso l’ospedale universitario di Heidelberg e Friburgo in uno vasto studio su pazienti affetti da SM. Questo studio rivelerà se l’uso di EPO nelle fasi iniziali della SM durante la neurite ottica è sensato.
http://www.ncbi.nlm.nih.gov/pubmed/22926853
Ci potrebbe essere un collegamento con la ccsvi, guarda caso l' EPO viene utilizzata dagli atleti al fine di "aumentare il trasporto di ossigeno ai tessuti"
http://it.wikipedia.org/wiki/Eritropoietina
Abstract
OBJECTIVE:
Based on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis.
METHODS:
Patients with optic neuritis who attended the University Hospitals of Homburg/Saar, Göttingen, or Hamburg (Germany) were included in this double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov, NCT00355095). They were randomly assigned to groups receiving either 33,000IU recombinant human erythropoietin intravenously daily for 3 days or placebo as an add-on therapy to methylprednisolone. The primary outcome parameter was change in retinal nerve fiber layer (RNFL) thickness after 16 weeks. Secondary outcome parameters included optic nerve atrophy as assessed by magnetic resonance imaging, and changes in visual acuity, visual field, and visual evoked potentials (VEPs).
RESULTS:
Forty patients were assigned to the treatment groups (21/19 erythropoietin/placebo). Safety monitoring revealed no relevant issues. Thirty-seven patients (20/17 erythropoietin/placebo) were analyzed for the primary endpoint according to the intention-to-treat protocol. RNFL thinning was less apparent after erythropoietin treatment. Thickness of the RNFL decreased by a median of 7.5μm by week 16 (mean ± standard deviation, 10.55 ± 17.54μm) compared to a median of 16.0μm (22.65 ± 29.18μm) in the placebo group (p = 0.0357). Decrease in retrobulbar diameter of the optic nerve was smaller in the erythropoietin group (p = 0.0112). VEP latencies at week 16 were shorter in erythropoietin-treated patients than in the placebo group (p = 0.0011). Testing of visual functions revealed trends toward an improved outcome after erythropoietin treatment.
INTERPRETATION:
These results give the first indications that erythropoietin might be neuroprotective in optic neuritis.
Copyright © 2012 American Neurological Association.
http://www.ncbi.nlm.nih.gov/pubmed/22926853
Ci potrebbe essere un collegamento con la ccsvi, guarda caso l' EPO viene utilizzata dagli atleti al fine di "aumentare il trasporto di ossigeno ai tessuti"
http://it.wikipedia.org/wiki/Eritropoietina
Abstract
OBJECTIVE:
Based on findings in animal models of autoimmune optic nerve inflammation, we have assessed the safety and efficacy of erythropoietin in patients presenting with a first episode of optic neuritis.
METHODS:
Patients with optic neuritis who attended the University Hospitals of Homburg/Saar, Göttingen, or Hamburg (Germany) were included in this double-blind, placebo-controlled, phase 2 study (ClinicalTrials.gov, NCT00355095). They were randomly assigned to groups receiving either 33,000IU recombinant human erythropoietin intravenously daily for 3 days or placebo as an add-on therapy to methylprednisolone. The primary outcome parameter was change in retinal nerve fiber layer (RNFL) thickness after 16 weeks. Secondary outcome parameters included optic nerve atrophy as assessed by magnetic resonance imaging, and changes in visual acuity, visual field, and visual evoked potentials (VEPs).
RESULTS:
Forty patients were assigned to the treatment groups (21/19 erythropoietin/placebo). Safety monitoring revealed no relevant issues. Thirty-seven patients (20/17 erythropoietin/placebo) were analyzed for the primary endpoint according to the intention-to-treat protocol. RNFL thinning was less apparent after erythropoietin treatment. Thickness of the RNFL decreased by a median of 7.5μm by week 16 (mean ± standard deviation, 10.55 ± 17.54μm) compared to a median of 16.0μm (22.65 ± 29.18μm) in the placebo group (p = 0.0357). Decrease in retrobulbar diameter of the optic nerve was smaller in the erythropoietin group (p = 0.0112). VEP latencies at week 16 were shorter in erythropoietin-treated patients than in the placebo group (p = 0.0011). Testing of visual functions revealed trends toward an improved outcome after erythropoietin treatment.
INTERPRETATION:
These results give the first indications that erythropoietin might be neuroprotective in optic neuritis.
Copyright © 2012 American Neurological Association.
Commenti
Posta un commento